Repligen
RGEN
#2566
Rank
โ‚ฌ5.98 B
Marketcap
106,20ย โ‚ฌ
Share price
-6.28%
Change (1 day)
-13.41%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of December 2025 : โ‚ฌ0.58 Billion

According to Repligen 's latest financial reports the company's total debt is โ‚ฌ0.58 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2025)

Total debt by year

Year Total debt Change
2025-12-31โ‚ฌ0.58 B-10.94%
2024-12-31โ‚ฌ0.65 B2.42%
2023-12-31โ‚ฌ0.64 B63.3%
2022-12-31โ‚ฌ0.39 B21.99%
2021-12-31โ‚ฌ0.32 B44.35%
2020-12-31โ‚ฌ0.22 B-4.74%
2019-12-31โ‚ฌ0.23 B159.84%
2018-12-31โ‚ฌ90.46 M9.36%
2017-12-31โ‚ฌ82.71 M-8.67%
2016-12-31โ‚ฌ90.57 M
2005-03-31โ‚ฌ0.09 M34.1%
2004-03-31โ‚ฌ0.06 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
โ‚ฌ54.60 B 9,170.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
โ‚ฌ33.62 B 5,608.40%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
โ‚ฌ17.49 B 2,870.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ40.24 B 6,732.25%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
โ‚ฌ21.7 M-96.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚ฌ0.21 B-63.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚ฌ0.35 B-39.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
โ‚ฌ0.29 B-49.14%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚ฌ0.51 B-12.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
โ‚ฌ2.19 B 272.55%๐Ÿ‡บ๐Ÿ‡ธ USA